{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:26:39Z","timestamp":1768033599762,"version":"3.49.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012173","name":"China-Japan Friendship Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to compare the efficacy and safety for particular regimen and dosage in venous thromboembolism (VTE) patients with renal insufficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>English language searches of PubMed, Embase, and Web of Science (inception to May 2021). RCTs evaluating anticoagulants for VTE treatment at acute phase, extension phase, and VTE prophylaxis in patients with renal insufficiency and reporting efficacy (death, recurrence, or occurrence of VTE) and safety (bleeding) outcomes were selected. The methodological quality of each study included was assessed at the outcome level using the risk-of-bias assessment tool developed by the Cochrane Bias Methods Group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-one trials that involved 76,574 participants and 8,972 (11.7%) patients with renal insufficiency were enrolled, including 10 trials on VTE treatment in acute phase (3\u201312 months), four trials on VTE treatment in extension phase (6\u201336 months), and seven trials for VTE prophylaxis. For acute VTE treatment, compared with dabigatran etexilate, apixaban (RR 5.90, 95%CI 1.00\u201334.60) and rivaroxaban (RR 6.18, 95%CI 1.17\u201332.75) were significantly associated with increased risk of death or recurrence. For extension treatment of VTE, aspirin had the highest probability of the most effective and safest treatment, followed by apixaban. For VTE prophylaxis, compared with enoxaparin, desirudin was associated with lower risk of VTE occurrence (RR 0.56, 95% CI 0.34\u20130.91), but had higher risk of bleeding than dabigatran etexilate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The network meta-analysis informs the optimal choice of anticoagulants and their particular dosage for treatment and prophylaxis of VTE patients comorbid renal insufficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier: CRD42021254086.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.979911","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T05:47:06Z","timestamp":1664171226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulant for treatment and prophylaxis of venous thromboembolism patients with renal dysfunction: A systematic review and network meta-analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Guohui","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xufei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenguo","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1053\/ajkd.2002.32774","article-title":"Chronic dialysis patients have high risk for pulmonary embolism","volume":"39","author":"Tveit","year":"2002","journal-title":"Am J Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000064282","article-title":"Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests","volume":"91","author":"Sirolli","year":"2002","journal-title":"Nephron."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S0140-6736(98)07534-5","article-title":"Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)","volume":"353","author":"Goldhaber","year":"1999","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.amjmed.2006.04.028","article-title":"Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry","volume":"119","author":"Monreal","year":"2006","journal-title":"Am J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1055\/s-0040-1712459","article-title":"Renal insufficiency and short-term outcomes of acute pulmonary embolism: a systemic review and meta-analysis","volume":"120","author":"Wang","year":"2020","journal-title":"Thromb Haemost."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1800445","DOI":"10.1183\/13993003.00445-2018","article-title":"Management appropriateness and outcomes of patients with acute pulmonary embolism","volume":"51","author":"Jim\u00e9nez","year":"2018","journal-title":"Eur Respir J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.chest.2021.06.048","article-title":"An original risk score to predict early major bleeding in acute pulmonary embolism: the syncope, anemia, renal dysfunction (PE-SARD) bleeding score","volume":"160","author":"Chopard","year":"2021","journal-title":"Chest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb Haemost."},{"key":"B14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism-analysis of the CATCH study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai-VTE","year":"2013","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11239-016-1386-8","article-title":"Post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment","volume":"42","author":"Woodruff","year":"2016","journal-title":"J Thromb Thrombolysis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN","year":"2010","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN\u2013PE","year":"2012","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.thromres.2011.03.002","article-title":"Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep\u00ae in Renal Insufficiency Study (IRIS)","volume":"128","author":"Leizorovicz","year":"2011","journal-title":"Thromb Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"New England Journal of Medicine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1055\/s-0039-1701009","article-title":"Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials","volume":"120","author":"Weitz","year":"2020","journal-title":"Thromb Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness","volume":"379","author":"Spyropoulos","year":"2018","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/j.1538-7836.2012.04803.x","article-title":"Impact of stage 3B chronic kidney disease on thrombosis and bleeding outcomes after orthopedic surgery in patients treated with desirudin or enoxaparin: insights from a randomized trial","volume":"10","author":"Shorr","year":"2012","journal-title":"J Thrombosis and Haemostasis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00264-011-1393-5","article-title":"Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement","volume":"36","author":"Dahl","year":"2011","journal-title":"Int Orthop."},{"key":"B30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/jth.12109","article-title":"Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups","volume":"11","author":"Pineo","year":"2013","journal-title":"J Thromb Haemost."},{"key":"B31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MNH.0000000000000098","article-title":"Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease","volume":"24","author":"Harel","year":"2015","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.2215\/CJN.04550511","article-title":"Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation","volume":"6","author":"Winkelmayer","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.kint.2018.11.011","article-title":"Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET)","volume":"95","author":"Wang","year":"2019","journal-title":"Kidney Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1093\/ndt\/gfq179","article-title":"Chronic kidney disease and venous thromboembolism: a prospective study","volume":"25","author":"Folsom","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1055\/s-0038-1676522","article-title":"The prognostic value of renal function in acute pulmonary embolism-a multi-centre cohort study","volume":"119","author":"Kostrubiec","year":"2019","journal-title":"Thromb Haemost."},{"key":"B39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/jcm8020160","article-title":"Assessment of renal dysfunction improves the simplified pulmonary embolism severity index (sPESI) for risk stratification in patients with acute pulmonary embolism","volume":"8","author":"Trimaille","year":"2019","journal-title":"J Clin Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.907.907","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","author":"Lim","year":"2006","journal-title":"Ann Int Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1053\/j.ajkd.2003.11.012","article-title":"Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease","volume":"43","author":"Farooq","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.979911\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T05:47:10Z","timestamp":1664171230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.979911\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":42,"alternative-id":["10.3389\/fmed.2022.979911"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.979911","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"article-number":"979911"}}